SynCon MERS DNA vaccine: Phase I started

Inovio began an open-label, dose-ranging, U.S. Phase I trial to evaluate a 3-injection regimen of 0.67, 2 and 6 mg DNA per intramuscular dose of GLS-5300 followed by electroporation in about 75 health...